positive
Recently
Rubicon Research – Strong Financials and US FDA Presence
No Image
Rubicon Research shows strong growth, US FDA approvals, and expanding pharma portfolio.
Rubicon Research, incorporated in 1999, specializes in differentiated pharmaceutical formulations. The company has 72 ANDA/NDA products approved by the US FDA and generated USD 195 million revenue from the US market in FY2024. Between FY2024-25, revenue rose 49% and PAT 48%. With 3 manufacturing facilities in India and 2 R&D units in India & Canada, it has a robust pipeline of 63 products in development.